Kronos Bio, Inc. (KRON) Stock Price, Quote & News - Stock Analysis (2024)

Table of Contents
About KRON Financial Performance Analyst Forecast News Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer Kronos Bio Reports First-Quarter 2024 Financial Results Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results How Does Kronos Stock Look After Its 15% Rise Last Week? Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13 Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate Development Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial Results Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance Kronos Bio Announces Participation in Upcoming Investor Conferences Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial Results

About KRON

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California. [Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 9, 2020

Employees 63

Stock Exchange NASDAQ

Ticker Symbol KRON

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for KRON stock is "Strong Buy." The 12-month stock price forecast is $4.13, which is an increase of 300.97% from the latest price.

Price Target

$4.13

(300.97% upside)

Analyst Consensus: Strong Buy

Stock Forecasts

News

Kronos Bio, Inc. (KRON) Stock Price, Quote & News - Stock Analysis (1)

Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer

— KB-0742 cleared 80mg four-days-on, three-days-off dosing schedule in dose escalation — — Company expects to provide an efficacy update on this expansion cohort in 1H 2025 — SAN MATEO, Calif. and CAM...

17 days ago - GlobeNewsWire

Kronos Bio, Inc. (KRON) Stock Price, Quote & News - Stock Analysis (2)

Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

— KB-0742 continues to demonstrate a manageable safety and tolerability profile with no grade 3/4 neutropenia observed —

2 months ago - GlobeNewsWire

Kronos Bio, Inc. (KRON) Stock Price, Quote & News - Stock Analysis (4)

Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer

SAN MATEO, Calif. and CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other d...

2 months ago - GlobeNewsWire

Kronos Bio, Inc. (KRON) Stock Price, Quote & News - Stock Analysis (5)

Kronos Bio Reports First-Quarter 2024 Financial Results

— $152.0 million cash runway into the second half of 2026 — — A study update on KB-0742-1001 will be presented at the upcoming American Society of Clinical Oncology (ASCO); expansion cohorts at new do...

3 months ago - GlobeNewsWire

Kronos Bio, Inc. (KRON) Stock Price, Quote & News - Stock Analysis (6)

Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results

Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half ...

5 months ago - GlobeNewsWire

Kronos Bio, Inc. (KRON) Stock Price, Quote & News - Stock Analysis (7)

How Does Kronos Stock Look After Its 15% Rise Last Week?

Kronos Worldwide KRO (NYSE: KRO), a titanium dioxide pigments (TiO2) producer and marketer, has gained around 15% in a week, considerably outperforming the broader Russell 2000 index which remains dow...

5 months ago - Forbes

Kronos Bio, Inc. (KRON) Stock Price, Quote & News - Stock Analysis (8)

Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway

Company to assess KB-0742 at planned new dose schedule in ongoing phase 1/2 study; topline data from expansion cohort at new dose schedule expected in the first half of 2025

5 months ago - GlobeNewsWire

Kronos Bio, Inc. (KRON) Stock Price, Quote & News - Stock Analysis (9)

Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced t...

5 months ago - GlobeNewsWire

Kronos Bio, Inc. (KRON) Stock Price, Quote & News - Stock Analysis (10)

Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference

SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced pa...

5 months ago - GlobeNewsWire

Kronos Bio, Inc. (KRON) Stock Price, Quote & News - Stock Analysis (11)

Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement

Company eliminates three executive officer roles and appoints new Executive Leadership team Company eliminates three executive officer roles and appoints new Executive Leadership team

7 months ago - GlobeNewsWire

Kronos Bio, Inc. (KRON) Stock Price, Quote & News - Stock Analysis (12)

Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate

Phase 1b portion of phase 1b/2 lanraplenib study in patients withrelapsed/refractory FLT3-mutated acute myeloid leukemia completed; review of data does not support continuing to phase 2

8 months ago - GlobeNewsWire

Kronos Bio, Inc. (KRON) Stock Price, Quote & News - Stock Analysis (13)

Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced th...

8 months ago - GlobeNewsWire

Kronos Bio, Inc. (KRON) Stock Price, Quote & News - Stock Analysis (14)

Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced th...

9 months ago - GlobeNewsWire

Kronos Bio, Inc. (KRON) Stock Price, Quote & News - Stock Analysis (15)

Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results

Company presented positive preliminary data from Phase 1 dose escalation portion of Phase 1/2 KB-0742 study at the AACR-NCI-EORTC and CTOS conferences

9 months ago - GlobeNewsWire

Kronos Bio, Inc. (KRON) Stock Price, Quote & News - Stock Analysis (16)

Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study

Strategic resource allocation to fully explore KB-0742's potential in both dose escalation and expansion cohorts across multiple tumor types in its ongoing Phase 1/2 study

10 months ago - GlobeNewsWire

Kronos Bio, Inc. (KRON) Stock Price, Quote & News - Stock Analysis (17)

Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting

Brian Van Tine, M.D., of Washington University School of Medicine, shares data from the ongoing phase 1/2 KB-0742 clinical study that clearly corresponds with the findings from the pre-clinical studi...

10 months ago - GlobeNewsWire

Kronos Bio, Inc. (KRON) Stock Price, Quote & News - Stock Analysis (18)

Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting

Brian Van Tine, M.D., of Washington University School of Medicine to share data from the ongoing Phase 1/2 study at leading international sarcoma meeting

10 months ago - GlobeNewsWire

Kronos Bio, Inc. (KRON) Stock Price, Quote & News - Stock Analysis (19)

Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC

Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors

10 months ago - GlobeNewsWire

Kronos Bio, Inc. (KRON) Stock Price, Quote & News - Stock Analysis (20)

Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13

Management to host conference call and webcast on October 13 at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D., of City of Hope Management to host con...

11 months ago - GlobeNewsWire

Kronos Bio, Inc. (KRON) Stock Price, Quote & News - Stock Analysis (21)

Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate Development

SAN MATEO, Calif. and CAMBRIDGE, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, announced that its...

1 year ago - GlobeNewsWire

Kronos Bio, Inc. (KRON) Stock Price, Quote & News - Stock Analysis (22)

Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial Results

Data from the Phase 1 dose escalation portion of the Phase 1/2 KB-0742 study will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 20...

1 year ago - GlobeNewsWire

Kronos Bio, Inc. (KRON) Stock Price, Quote & News - Stock Analysis (23)

Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance

Dr. Besman brings more than 25 years of regulatory affairs and drug development experienceand a track record of successfully advancing clinical programs Dr. Besman brings more than 25 years of regula...

1 year ago - GlobeNewsWire

Kronos Bio, Inc. (KRON) Stock Price, Quote & News - Stock Analysis (24)

Kronos Bio Announces Participation in Upcoming Investor Conferences

SAN MATEO, Calif. and CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced th...

1 year ago - GlobeNewsWire

Kronos Bio, Inc. (KRON) Stock Price, Quote & News - Stock Analysis (25)

Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial Results

Enrollment ongoing in expansion portion of Phase 1/2 KB-0742 study, with initial efficacy data expected in 2H 2023 Phase 1b/2 study of lanraplenib in combination with gilteritinib in FLT3-mutated AML ...

1 year ago - GlobeNewsWire

Kronos Bio, Inc. (KRON) Stock Price, Quote & News - Stock Analysis (2024)
Top Articles
Latest Posts
Article information

Author: Errol Quitzon

Last Updated:

Views: 6637

Rating: 4.9 / 5 (79 voted)

Reviews: 94% of readers found this page helpful

Author information

Name: Errol Quitzon

Birthday: 1993-04-02

Address: 70604 Haley Lane, Port Weldonside, TN 99233-0942

Phone: +9665282866296

Job: Product Retail Agent

Hobby: Computer programming, Horseback riding, Hooping, Dance, Ice skating, Backpacking, Rafting

Introduction: My name is Errol Quitzon, I am a fair, cute, fancy, clean, attractive, sparkling, kind person who loves writing and wants to share my knowledge and understanding with you.